Skip to main content
Explore URMC



New Issue of Opportunities to Explore, April 12- April 16, 2021

Friday, April 9, 2021

The new issue of opportunities to explore is out now!

Read the April 12-April 16, 2021 Issue

Ian Krout wins the People’s Choice award for SOT’s 3 Minute Thesis

Wednesday, March 24, 2021


Ian Krout

Congratulations to Ian Krout for winning the People’s Choice award for SOT’s 3 Minute Thesis! Krout is a 3rd year Toxicology student, in Matt Rand's Lab, whose interests lie in both methylmercury toxicity as well as the gut microbiomes role in the field of toxicology. His research is focused on elucidating the microbial mechanisms of the gut that give rise to inter-individual differences in methylmercury elimination from person to person. It is focused on investigating the bacterial species at play in the microbiome, the mechanisms used for biotransformation, and what this means for the overall elimination rate and subsequent toxicity of differing mercury compounds.

Congrats Ian!

Wedekind lab research featured on the cover of JBC “The Year in JBC: 2020" issue

Friday, February 12, 2021

Congratulations to Shashank Chavali, Dr. Sachitanand Mali, Dr. Jermaine Jenkins, Dr. Rudi Fasan, and Dr. Joseph Wedekind for being featured on the cover of JBC “The Year in JBC: 2020" issue. Their recent research article, published in the Journal of Biological Chemistry (JBC) December 4, 2020 issue, titled “Co-crystal structures of HIV TAR RNA bound to lab-evolved proteins show key roles for arginine relevant to the design of cyclic peptide TAR inhibitors” has been selected as the representative ‘RNA’ article for 2020 retrospective collection called “The Year in JBC: 2020.”

The cover art below, shows a collage of fluorescence complementation experiments between the [4Fe-4S]-transferring NFU1 and potential partners (performed by Roland et al.), crystal structure overlays of HIV-1 TAR RNA with lab-evolved TAR-binding proteins (reported by Chavali et al.), nonmelanized yeast cells (explored by Chrissian et al.) and a cryo-EM structure of STEAP1, now thought to function as a ferric reductase in heterotrimer form (reported by Oosterheert and Gros). Artwork created by EJ Marklin.



Read More: Wedekind lab research featured on the cover of JBC “The Year in JBC: 2020" issue

Lynne Maquat Awarded 2021 Wolf Prize in Medicine

Tuesday, February 9, 2021

Lynne Maquat


Lynne E. Maquat, Ph.D., the founding director of the Center for RNA Biology at the University of Rochester, was honored with the 2021 Wolf Prize in Medicine. The acclaimed international award is given to outstanding scientists from around the world for achievements that benefit mankind. 

Maquat was selected for “fundamental discoveries in RNA biology that have the potential to better human lives.” She has spent her career deciphering the many roles that RNA plays in sickness and in health, and is well known for her discovery of nonsense-mediated mRNA decay or NMD. One of the major surveillance systems in the body, NMD protects against mistakes in gene expression that lead to disease. Maquat’s lab also revealed that NMD helps our cells adjust to changes in development and in their environment, and more rapidly respond to certain stimuli.

Maquat shares the award with Joan Steitz, Ph.D., Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine and Adrian Krainer, Ph.D., St. Giles Foundation Professor and Cancer Center Deputy Director of Research at Cold Spring Harbor Laboratory. Steitz and Krainer were also honored for discoveries in RNA biology.

The Wolf Foundation, which celebrates exceptional achievements in the sciences and the arts, is based in Israel, where Maquat’s quest to unravel the intricacies of NMD began. In 1980 she traveled to Jerusalem to retrieve bone marrow samples from four children suffering from thalassemia major, the most severe form of the inherited blood disorder thalassemia. Maquat wanted to learn why the children’s marrow contained no beta-globin protein, which is necessary for the oxygen-carrying function of red blood cells. Her 1981 breakthrough manuscript, “Unstable beta-globin mRNA in mRNA-deficient beta0 thalassemia,” published in Cell, was the first to reveal the role of NMD in human cells and how it can lead to disease.

“Lynne’s work on nonsense-mediated mRNA decay is the bedrock of an ever-growing body of research on how mRNAs are monitored and regulated,” said Mark B. Taubman, M.D., dean of the University of Rochester School of Medicine and Dentistry. “Her dedication to her science and to the field of RNA biology has opened the door to the development of RNA-based therapeutics for a wide range of disorders that you can’t reach with conventional drugs. We’re thrilled that her contributions are being recognized with this prestigious award.”

RNA secured its place in the public eye in 2020 with the development and approval of multiple mRNA COVID-19 vaccines. Years of research by Maquat, Steitz and Krainer helped set the stage for the rapid development of these vaccines.

The J. Lowell Orbison Endowed Chair and Professor in the Department of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry, Maquat is the recipient of several other significant honors, including:

Winners of the Wolf Prize are selected annually by an international jury committee of the Wolf Foundation; prizes are awarded regardless of religion, gender, race, geographical region, or political view. The official announcement of this year’s prize by the President of the State of Israel, Reuven Rivlin, was made on February 9, 2021.

Read More: Lynne Maquat Awarded 2021 Wolf Prize in Medicine

Miriam Barnett chosen to be a 2021 ASPET Washington Fellow

Tuesday, January 19, 2021

Miriam Barnett

Miriam Barnett, a Pharmacology graduate student in Dr. Jean Bidlack’s lab, was chosen to be a 2021 American Society for Pharmacology and Experimental Therapeutics (ASPET) Washington Fellow. The mission of the ASPET Washington Fellows Program is to enable developing and early career scientists interested in science policy to learn about and become more engaged in public policy issues. Miriam’s selection was based on her strong interest in science and its intersection with public policy. As an ASPET Washington Fellow, Miriam will meet with congressional representatives and staff to advocate for the importance of biomedical research.